Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Aesthet Surg J ; 27(3): 294-5; author reply 296, 2007.
Article in English | MEDLINE | ID: mdl-19341657
3.
Dermatol Ther ; 19(3): 129-33, 2006.
Article in English | MEDLINE | ID: mdl-16784511

ABSTRACT

As an increasing number of patients seek esthetic improvement through minimally invasive procedures, interest in soft tissue augmentation and filling agents is at an all-time high. One reason for this interest is the availability of botulinum toxin type A, which works superbly in the upper face. The rejuvenation of the upper face has created much interest in injectable filling agents and implant techniques that work equally well in the restoration of the lower face. One of the central tenets of soft tissue augmentation is the concept of the three-dimensional face. The youthful face has a soft, full appearance, as opposed to the flat, pulled, two-dimensional look often achieved by more traditional surgical approaches. Injectable filling agents can augment and even at times, replace pulling. Additionally, with the lip as the focal center of the lower face, subtle lip enhancement is here to stay, and is in fact, the number one indication for injectable fillers. Moreover, minimally invasive soft tissue augmentation offers cosmetic enhancement without the cost and recovery time associated with more invasive procedures. As more and more physicians take interest in minimally invasive surgery, courses in cosmetic surgery techniques are becoming increasingly popular at the medical meetings of many specialties. Today, physicians have a much larger armamentarium of techniques and materials with which to improve facial contours, ameliorate wrinkles, and provide esthetic rejuvenation to the face. For a substance or device to be amenable for soft tissue augmentation in the medical community, it must meet certain criteria. It must have both a high "use" potential, producing cosmetically pleasing results with a minimum undesirable reactions, and have a low abuse potential in that widespread or incorrect or indiscriminate use would not result in significant morbidity. It must be nonteratogenic, noncarcinogenic, and nonmigratory. In addition, the agent must provide predictable, persistent correction through reproducible implantation techniques. Finally, the substance, agent or device must be approved by the U.S. Food and Drug Administration, which assures purity, safety, and accessibility, as well as much-needed information regarding use. Having a thorough understanding of the filling agents available, their indications and contraindications, as well as having thorough knowledge of implant technique are vital in providing the patient with an esthetically pleasing result.


Subject(s)
Biocompatible Materials/administration & dosage , Collagen/administration & dosage , Cosmetic Techniques , Face , Hyaluronic Acid/administration & dosage , Rejuvenation , Biocompatible Materials/adverse effects , Collagen/adverse effects , Humans , Hyaluronic Acid/adverse effects , Injections
4.
J Am Acad Dermatol ; 54(2): 272-81, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16443058

ABSTRACT

BACKGROUND: Cosmetic dermatologic procedures offer the promise of visible aesthetic enhancement with minimal risk. While in recent years the number of available procedures has proliferated, there are few objective methods for evaluating the relative quality of these procedures for particular indications or specific patients. OBJECTIVE: (A) To develop a simple, easy-to-use numerical rating scale to assess the quality of cosmetic surgical procedures on a range of parameters pertaining to clinical efficacy and patient satisfaction; (B) to statistically validate the discriminative value of this rating scale. METHODS: (A) Patient and physician interviews were performed to elicit a list of factors that may collectively characterize the clinical efficacy and patient tolerability of cosmetic dermatologic procedures. A 0-100 point rating scale was developed based on these factors, with the face-validity of this scale checked by a group of patients and physicians; (B) Statistical analysis of the questionnaire was performed by asking 15 expert cosmetic dermatologic surgeons to use it to rate 23 common cosmetic dermatologic procedures, and analyzing the results. RESULTS: (A) An easy-to-use scale was constructed to assess the quality of cosmetic dermatologic procedures by rating the associated cost, risk, time (procedure and recovery), discomfort, results, and longevity of benefit. A "physician adjustment factor" was used to further increase the relevance of this 0-100 point scale for specific patients; (B) Repeated-measures analysis of variations (ANOVAs) performed on the data from the survey of experts demonstrated that this scale can be used to discriminate between common dermatologic procedures. The differences in mean subscores and total scores among procedures grouped by anatomic site and target lesion-type were significant at the level of P < .05. LIMITATIONS: Patient preferences exogenous to the rating scale may increase or decrease the suitability of specific procedures. CONCLUSIONS: Common cosmetic dermatologic procedures are of uniformly high quality, as per expert ratings on a systematic measure. This quality rating scale appears statistically valid and robust, given that expert raters assigned similar ratings to the same procedures but mean ratings were different across procedures. In the future, this quality rating scale can be used to assess novel interventions, and to help dermatologic surgeons faced with patient concern to optimally select among alternative procedures for a given indication.


Subject(s)
Plastic Surgery Procedures , Botulinum Toxins, Type A/therapeutic use , Chemexfoliation , Cryosurgery , Decision Making , Dermabrasion , Humans , Laser Therapy , Lipectomy , Neuromuscular Agents/therapeutic use , Patient Satisfaction , Plastic Surgery Procedures/adverse effects , Plastic Surgery Procedures/economics , Surveys and Questionnaires
5.
Aesthet Surg J ; 26(4): 444-5, author reply 445-6, 2006.
Article in English | MEDLINE | ID: mdl-19338928
9.
Clin Dermatol ; 22(1): 66-75, 2004.
Article in English | MEDLINE | ID: mdl-15158548

ABSTRACT

Cosmetic use of BTX has skyrocketed in recent years, especially since the approval of BTX-A for treatment of glabellar lines. Complications and adverse reactions can easily arise, particularly for the novice injector. This paper provides insights from an experienced physician on how to avoid these complications, and how to treat them when and if they occur. The main cosmetic uses for BTX are analyzed for possible complications and adverse events. Injection techniques are discussed. Comparisons between BTX-A and BTX-B are given to point out the need for different injection techniques based on the product being used. Treatment recommendations for the Glabella, Brow, Crow's Feet, Upper Lip Wrinkling/Lines, Depressor Anguli Oris, Nasolabial Folds, Mentalis, Neck and Hyperhidrosis are discussed, as well as systemic complications. It is important for the injecting physician to be familiar with these potential complications, even though the use of BTX has been safe and generally well tolerated, because it will lead to even greater success with the use of BTX.


Subject(s)
Botulinum Toxins, Type A/adverse effects , Neuromuscular Agents/adverse effects , Botulinum Toxins, Type A/administration & dosage , Contraindications , Face , Humans , Hyperhidrosis/drug therapy , Injections, Intramuscular , Migraine Disorders/drug therapy , Neuromuscular Agents/administration & dosage , Skin Aging , Torticollis/drug therapy
10.
Dermatol Surg ; 30(3): 452-5, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15008883

ABSTRACT

BACKGROUND: Botulinum toxin type A (BTX-A; commercial preparation BOTOX) is most well known for its effect on muscle contraction because of the BTX binding to the presynaptic nerve terminal, inhibiting the release of acetylcholine (ACH). The therapeutic benefit of BTX-A, however, can also be isolated to pain relief alone, suggesting that BTX-A also works through additional modes of action. OBJECTIVE: This article provides insight by an experienced physician into four different case reports. Each case demonstrates the therapeutic potential of BTX-A and the possibility of a different mechanism of action for BTX other than the inhibition of ACH release. RESULTS: Four patients, each with different symptoms such as relapsing-remitting multiple sclerosis, postherpetic neuralgia, peripheral neuropathy, and severe tingling caused by herniation of cervical vertebrae at the level of C8, were treated with BOTOX, and their symptoms were alleviated. CONCLUSIONS: The BTX-A mechanism providing pain relief is hypothesized to be something other than muscle relaxation by inhibiting the release of ACH at the neuromuscular juncture, such as inhibition of the release of substance P or the blocking of autonomic pathways, etc. This article is intended to continue to keep physicians using this substance for dermatologic indications aware of the potential unsuspected effects.


Subject(s)
Botulinum Toxins, Type A/therapeutic use , Neuromuscular Agents/therapeutic use , Pain/drug therapy , Adult , Female , Humans , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/drug therapy , Neuralgia/drug therapy
17.
Dis Mon ; 48(5): 336-56, 2002 May.
Article in English | MEDLINE | ID: mdl-12195264

ABSTRACT

Botulinum toxins are the causative agents of the severe food-borne illness botulism. With lethal doses approximating 10(-9) g/kg body weight, these neurotoxins represent some of the most toxic naturally occurring substances. Regardless, botulinum toxin is considered a safe therapy for inappropriate muscle spasms with adverse effects being typically self-limited. This article deals with some of the complications that have occurred with these treatments. The greatest concern with the use of BOTOX is probably the formation of blocking antibodies leading to nonresponse of subsequent treatment. Prevalence of resistance is less than 5%. Most complications associated with its aesthetic use are few and anecdotal. Nevertheless, the common problems and pitfalls associated with aesthetic treatment of the various areas of the face and neck with botulinum toxin are discussed. Also included are recommendations as to how to avoid these very undesirable, yet common, problems.


Subject(s)
Botulinum Toxins, Type A/adverse effects , Neuromuscular Agents/adverse effects , Blepharoptosis/chemically induced , Cosmetic Techniques/adverse effects , Diplopia/chemically induced , Drug Resistance , Ecchymosis/chemically induced , Ectropion/chemically induced , Humans , Hyperhidrosis/drug therapy , Informed Consent , Migraine Disorders/drug therapy , Skin Aging/drug effects , Spasm/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...